364 related articles for article (PubMed ID: 26912050)
21. Role of Immunotherapy in Head and Neck Cancer.
Ling DC; Bakkenist CJ; Ferris RL; Clump DA
Semin Radiat Oncol; 2018 Jan; 28(1):12-16. PubMed ID: 29173750
[TBL] [Abstract][Full Text] [Related]
22. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
24. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.
Blaszczak W; Barczak W; Wegner A; Golusinski W; Suchorska WM
Med Oncol; 2017 Apr; 34(4):60. PubMed ID: 28315228
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint immunotherapy in head and neck cancers.
Zolkind P; Uppaluri R
Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
[TBL] [Abstract][Full Text] [Related]
27. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for head and neck squamous cell carcinoma.
Li Q; Prince ME; Moyer JS
Oral Oncol; 2015 Apr; 51(4):299-304. PubMed ID: 25624094
[TBL] [Abstract][Full Text] [Related]
29. Targeted Therapy of Head and Neck Cancer.
Rieke DT; Klinghammer K; Keilholz U
Oncol Res Treat; 2016; 39(12):780-786. PubMed ID: 27889751
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the ASCO Meeting 2016].
Bußmann L; Busch CJ; Knecht R
HNO; 2016 Oct; 64(10):723-30. PubMed ID: 27604281
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression].
Brix N; Dunn L; Seiwert T; Belka C; Lauber K
Internist (Berl); 2020 Jul; 61(7):682-689. PubMed ID: 32462252
[TBL] [Abstract][Full Text] [Related]
32. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
33. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Moskovitz J; Moy J; Ferris RL
Curr Oncol Rep; 2018 Mar; 20(2):22. PubMed ID: 29502288
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy for squamous cell carcinoma of the head and neck.
Pancari P; Mehra R
Surg Oncol Clin N Am; 2015 Jul; 24(3):437-54. PubMed ID: 25979393
[TBL] [Abstract][Full Text] [Related]
37. The promise of immunotherapy in head and neck squamous cell carcinoma.
Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapeutic Approaches to Head and Neck Cancer.
Nasser H; St John M
Crit Rev Oncog; 2018; 23(3-4):161-171. PubMed ID: 30311572
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Therapy in Head and Neck Cancers.
Msaouel P; Massarelli E
Cancer J; 2016; 22(2):108-16. PubMed ID: 27111906
[TBL] [Abstract][Full Text] [Related]
40. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
